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INTRODUCTION 
 Diabetes mellitus is the most prevalent disease worldwide. India 
will become diabetic capital in the world by 2030. Now it is occupying 
second place in prevalence after China. Newer concepts and therapy for 
diabetes is on going worldwide. Trace elements like zinc plays a role in 
carbohydrate metabolism and affects blood glucose. Study on zinc and 
other trace elements effect on diabetes is limited. 
 Both microvascular and macrovascular complications in diabetes 
are related to oxidative stress. Zinc which has antioxidant property delays 
diabetic complications. Zinc has a role in insulin secretion from beta cell 
of pancreas.  
 Diabetes with zinc deficiency found to have uncontrolled 
hyperglycemia, insulin resistance and early onset diabetic microvascular 
and macrovascular complications. Long standing hyperglycemia is 
measured by HbA1c (glycated haemoglobin).  
 The study aims to correlate Zinc and HbA1c relationship in newly 
diagnosed Type 2 Diabetes mellitus. And also to compare zinc 
relationship with hypertension, obesity (body mass index), dyslipidemia ( 
triglyceride and cholesterol) in diabetes . 
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AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVES 
 To study the relationship between serum Zinc level and HbA1C 
level in newly diagnosed Type 2 Diabetes mellitus. 
SECONDARY OBJECTIVES 
1. To compare obesity, dyslipidemia, hypertension in diabetes and 
control. 
2. To compare serum Zinc level with obesity , hypertension and 
dyslipidemia. 
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REVIEW OF LITERATURE 
History  
 History of diabetes started around 1550 BC approximately.[19]. A 
rare disease is mentioned in Egyptian literature , disease that cause patient 
to urinate frequently and lose weight. 
Aretaeus(30-90CE), the great physician named “diabetes” meaning 
“flowing through”. He noticed a disease with symptoms of increased 
thirst (polydipsia), increasedurination (polyuria) and  weight loss.  
Galen (131-201CE) thought patient who complaints of increased 
urination and thirst are suffering from renal disease  . In the 17thcentury 
Dr. Thomas Willis, a London physician diagnosed patients with diabetes 
by testing their urine. He would diagnose diabetes if urine taste wassweet 
. “Mellitus” means “Honey” in Latin. until the 20th century, diabetes 
were monitored by this method. 
 Frederic Banting (Canadian medical scientist) and his colleagues 
discovered an essential harmone called insulin in 1921.The first oral 
hypoglycemic agent, sulfonylurea was discovered in France by 
pharmacology professor M.J. Janbon.he noticed lowering of blood sugar 
in  sulfonylurea treated typhoid patients . 
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Diabetes was first classified into  "insulin sensitive" (type I) and 
"insulin insensitive" (type II) in the year 1950. Later many form of 
diabetes was recognised. 
Aretaeus spoke of diabetes as "the mysterious sickness” 2000 years 
back. Since then physicians and scientists were contributing their 
knowledge to diabetes mellitus. And their knowledge made way in 
discovering wonderful harmone insulin and drug oral hypoglycemic 
agents.  Since then government, doctors  and pharmaceutical company 
working to make patient life easier. 
 
Epidemiology 
World 
The worldwide prevalence of DM has increased dramatically over 
the past 20 years. Its prevalence was estimated to 30 million cases in the 
year 1985 and now it has been increased to 382 million in the year 
2013[2]. International diabetes federation projects that  diabetes 
prevalence will reach 592 million by the year 2035. The countries with 
the greatest number of individuals with diabetes in 2013 are China (98.4 
million), India (65.1 million), United States (24.4 million), Brazil (11.9 
million) and Russia ( 10.9 million). 
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A recent data suggested that diabetes was responsible for almost 
8% of deaths or 5.1 million deaths worldwide in 2013. In 2013, it was 
estimated that  11% of health care expenditures or $548 billion were 
spent on diabetes patients worldwide. 
 
 
Figure 1 - Worldwide Diabetes Prevalence 
India 
 In 2013, People lives with diabetes reaches 65.1 million in india. It 
is estimated diabetes may reach to 101.2 million by the year 2030.[3] 
.In 2012 , one million people in india are died due to diabetes. In 
urban slums of chennai 1 out of 4 people living suffer from diabetes and 
this is three times higher than  national average of about 7% 
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 In india chronic disease is seen in more than 20% of diabetes 
population and more than 10 % of diabetes population  have more than 
one chronic disease. 
Table 1 – Prevalence of Diabetes & Prediabetes 
 
Definition 
 Diabetes mellitus is a disorder of metabolism characterised by 
hyperglycemia and it occurs as a result of  defects in insulin secretion, 
insulin action, or both. The chronic hyperglycemiaof diabetes is 
responsible for long term damage of organs that includes especially eye, 
kidney, heart, nerves and vessels. 
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Classification 
Diabetes can be classified into the following general categories: 
1. Type 1 diabetes mellitus ( b-cell destruction,  leads to absolute 
insulin deficiency) 
2. Type 2 diabetes mellitus ( progressive insulin secretory defect 
and insulin resistance) 
3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in 
pregnant woman  in the second or third trimester that is not clearly overt 
diabetes) 
4. Specific types of diabetes due to other causes: 
Monogenic diabetes syndromes (neonatal diabetes and MODY-
maturity onset diabetes of young), diseases of the exocrine pancreas ( 
pancreatitis, fibrocalculouspancreatopathycystic fibrosis), and drug 
induced diabetes (drugs used in treatment of HIV/AIDS or after organ 
transplantation) 
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Figure 2 – Classification of Diabetes 
 Type 2 DM is the most common type of  DM . Its prevalence is 
rising more rapidly due to 
 Increasing obesity 
 Dietary intake of processed, energy dense foods 
 Reduced physical activity 
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 Industrialisation  
 Aging of population. 
 Insulin resistance and abnormal insulin secretion are central to the 
pathogenesis of  type 2 DM . Type 2 DM has a strong genetic component 
than Type 1 DM. The concordance of type 2 diabetes in identical twins 
ranges between 70% and 90%.  Type 2 DM risk increases to 40% if both 
parents are diabetes. 
Clinical features 
 Most of patients are asymptomatic and hyperglycemia is noted on 
routine investigation. 
 Classic symptoms of hyperglycemia seen in DM are  polyuria, 
nocturia, polydipsia, burred vision and infrequently weight loss. Polyuria 
occurs when glucose in blood exceeds renal threshold that is above 
180mg/dl which results in glycosuria. Glycosuria causes osmotic diuresis 
(polyuria) and hypovolemia (dehydration) which in turn can lead to 
polydipsia. 
Prediabetes 
 Impaired fasting glucose and impaired glucose tolerance lead to 
diabetes in future .theseincludes group of people who do not meet the 
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criteria for diabetes and also doesnot fall in normal. They have high risk 
of developing diabetes if their glycemic status is not modified by 
lifestyle.  
Significance of Prediabetes 
 Increased risk of cardiovascular and cerebrovascular diseases. 
 Predictor of future diabetes mellitus.[4] 
.Diabetic range values may be unmasked with stress. 
Prediabetes criteria 
 Impaired fasting glucose 100 – 125 mg/dl. (fasting plasma glucose) 
 Impaired glucose tolerance 140 – 199mg/dl. (2 hr PG in the 75 g 
OGTT) 
 HbA1c  5.7 – 6.4% 
Metabolic syndrome  
 Syndrome X or insulin resistance syndrome 
 It is characterise by abdominal obesity, dyslipidemia, hypertension 
and glucose intolerance. Insulin resistance and hyperinsulinemia plays a 
central role in pathogenesis. It exhibits a proinflammatory state and is 
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associated with high levels of apolipoprotein B and elevated level of 
small LDL particles as well as a two foldrisk for developing 
cardiovascular disease.[5] and a five fold  risk for developing  type 2 
diabetes. 
 Table 2 – Metabolic Syndrome Criteria 
 
Criteria for diagnosis of Diabetes Mellitus 
 HbA1c> 6.5%. (or) 
 Fasting Plasma Glucose > 126 mg/dl (7.0 mmol/L). (or) 
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 2 hr Prandial Glucose > 200 mg/dl (11.1 mmol/L) during an 
OGTT. (or) 
 In a patient with classic symptoms of hyperglycemia or 
hyperglycemic crisis, a random plasma glucose > 200 mg/dl (11.1 
mmol/L). 
 HbA1c test should be performed using a method that is certified by 
NGSP  and standardised to DCCT assay. Fasting is defined as patient has 
no intake of calorie for atleast 8 hrs. OGTT test should be performed 
using a glucose load (75 gm anhydrous glucose dissolved in water) as 
described by WHO.[6] 
 In the absence of unequivocal hyperglycemia, results should be 
confirmed by repeat testing . 
Screening 
 Screening of asymptomatic risk individuals plays a important role 
in reducing morbidity and mortality from diabetes .screening should be 
done in any person with BMI >25 (or >  23 in Asian) with > 1 diabetic 
risk factor 
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Risk individuals 
 1.First degree relative with diabetes 
 2.Women who delivered a baby more than 9lb or were diagnosed 
with GDM 
3.Hypertensive patient that is BP > 140/90 mm Hg or on 
antihypertensive drugs 
4.High risk race / ethnicity 
5.Physical inactivity                                                                                                           
6.Insulin resistance conditions like obesity, polycystic ovarian 
syndrome,acanthosisnigricans. 
 7.HDL cholesterol < 35 mg/dl + triglyceride > 250 mg/dl 
8.Cardiovascular disease history 
9.Prediabetes 
Glycemic targets 
 HbA1c <7.0 ,preprandial plasma glucose 80 to 130 mg/dl, 2 hr post 
prandial < 180 mg,dl. Achieving this target helps in reducing 
microvascular and macrovascular complications. More stringent target is 
HbA1c < 6.5, less stringet target is HbA1c < 8. Target is based on age / 
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life expectancy, diabetic durations, hypoglycemic status, individual 
patient considerations, comorbid conditions and known cardiovascular or 
microvascular complications.[7] 
Treatment of type 2 DM  
1. Life style modifications 
2. Hypoglycemic Drugs + insulin therapy. 
Life style modifications include eating a balanced diet and 
regular exercise. Balanced dietconsists of carbohydrate (50-60% 
of total calories),protein(15 to 20%), total fat(25-35% ). 
Saturated fat should be less than 7% of total calories.Low 
calorie diet and exercise plays a role in weight reduction as type 
2 DM are obese often. Weight reduction decreases insulin 
resistance and improves glycemic control. 
 Simple carbohydrates like monosaccharides ( fructose, glucose, 
galactose) and dissacharides (sucrose, maltose, lactose) increase blood 
gluose rapidly. So diabetic patients should avoid simple carbohydrates. 
Complex carbohydrates like starch and dietary fibre should be the major 
form of carbohydrates.[8] 
 Dietary fibre is not metabolised in small intestine due to lack of 
enzyme for it. Benefits  of dietary fibre include  reduce total calorie by 
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increasing satiety, relieves constipation by increasing bulk of feces, 
improves glucose tolerance by prolonging gastric emptying and slow 
absorption of glucose, reduces cholesterol in blood by binding in small 
intestine and excrete as bile acid. 
 Gycemic index is the ability of carbohydrate to raise blood glucose. 
Diabetic patient should choose one low glycemic index food at each 
meal, combine a high glycemic index food along with low) glycemic food 
( rice with dal)[9] 
 Glycemic load is carbohydrate content in food based on glycemic 
index. Eg potato glycemic index is 80 , 100 gm potato contains 23 gram 
of carbohydrate so glycemic load is 23x80/100 = 18. 
  
 Table 3 
 Protein has high satiety index, reduce GI of food, slow the gastric 
emptying time. Daily intake recommended is 1g/kg body weight. 
Diabetic patients should restrict saturated fatty acids , trans fatty acids 
and cholesterol. Diets rich in monounsaturated fatty acids decrease 
insulin resistance.  
 
16 
–GlycemicIndex and Glycemic Load 
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 Diets should include 25 to 35% calorie from fat , recommended is 
20% from MUFA(monounsaturated fatty acids),  10% from PUFA( 
polyunsaturated fatty acids, less than 7 % from SFA ( saturated fatty 
acids). Foods that contains omega 3 fatty acids offer cardioprotective 
effects. 
 
Figure 3 – Dietary fats in various Oil. 
Recommended calorie intake in diabetic patient 
 Obese -  20 Kcal/kg 
 Normal BMI , sedentary men / women   22 – 25 Kcal/kg 
 Normal BMI, active men / women  - 30 Kcal/kg 
          Thin / very active  - 40 Kcal/kg 
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 Physical activity includes “SAFE” exercise S- strengthening 
exercise, A- aerobic exercise, F- flexibility exercise, E- endurance 
exercise.[11] 
. Strengthening exercise use muscle strength to move a resistive load 
(eg, weight lifting and exercise using weight machine). 
 Aerobic exercise consists of repeated rhythmic continuous 
movements of large muscle groups ( eg walking, cycling, swimming). 
Recommended timing of aerobic exercise for diabetes is 30 to 40 minutes 
per day for atleast 5 days a week. 
   Flexibility exercise aims at improving muscle tone and body 
control ( eg stretch exercise).  
 Endurance exercise refers to exercise with low intensity and sustain 
activity for prolonged period( eg cycling, swimming for prolonged period 
increases cardiorespiratory endurance).  
 Non weight bearing exercise for people with severe obesity and 
joint degeneration. 
 FITT principle should be applied while doing exercise, F 
(frequency) - 4 to 6 times a week, I (intensity) - to achieve 50 to 80% of 
target heart rate, T( type) - safe exercise , T ( timing) -  morning. Brisk 
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walking is the best aerobic exercise which needs no training and easily 
done. 
Oral antidiabetic agents  
Table 4 – Antidiabetic drugs 
 
 Initiate monotherapy depending on patient weight ,glycemic status, 
and other comorbidities. If not controlled with monotherapy , then try 
double or triple combination. Finally insulin is added for control of  blood 
glucose. 
  
20 
 
Insulin  
Table 5 – Insulin properties 
 
Complications of diabetes mellitus 
 Acute life threatening conditions includes hypoglycaemia, diabetic 
ketoacidosis, hyperosmolarhyperglycemic state. Chronic complications 
include  microvascular and macrovascular disease. 
  Microvascular complications are diabetic retinopathy, diabetic 
neuropathy, diabetic nephropathy. Macrovascular complcations are 
cardiovascular disease ( myocardial infarction, ischemic cardiomyopathy 
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), cerebrovascular disease ( ischemic stroke), peripheral arterial disease ( 
gangrene and foot ulcer). 
Hypoglycemia 
 It is defined by ADA and EASD as serum glucose less than 70 
mg/dl. An alternate definition is decrease in blood glucose with 
symptoms of hypoglycaemia. Hypoglycaemia symptoms are neurological 
changes ( altered mental status  , seizures, focal deficit)  and sympathetic 
overactivity( sweating, palpitaition , tremor,).  
  It occurs as a result of medication overdose, diet changes, 
infections and metabolic changes. Fasting during ramzan, hepatic disease, 
adrenal insufficiency and starvation are all causes of hypoglycaemia. 
Drugs like oral hypoglycemic, sulphonamides, insulin, haloperidol, 
diuretics, salicylates, ethanaol, p-aminobenzoic acid, quinine can cause 
hypoglycaemia. 
Treatment is based on patient ability to take orally. Those who can 
take orally should be given oral glucose , chocolate followed by complex 
carbohydrate. Patient who cannot take orally should be treated with 
intravenous glucose .initially 20 ml of 50 % dextrose bolus and then 5% 
dextrose at 100 ml/ hr until stabilised. Blood glucose should be monitored 
frequently until it reaches 100 mg/dl. After stabilising the patient cause of 
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hypoglycaemia should be evaluated and further management shoud be 
planned. 
Diabetic ketoacidosis &Hyperosmolar Hyperglycemic 
state 
 DKA is characterised by triad of hyperglycemia, ketonemia and 
anion gap metabolic acidosis. It frequently occurs in type 1 DM but can 
also occurs in type 2 DM in extreme stress such as severe infection , 
trauma and cardiovascular emergency[11] 
.Precipitating factors 
 Inadequate insulin treatment or noncompliance,  
 New onset diabetes , insulin pump dysfunction, trauma , surgery, 
 Acute illness like infection, cerebro and cardiovascular accidents, 
 Drugs like olanzapine, cocaine, thiazide, terbutaline, steroids, 
dobutamine 
 HHS is characterised by hyperglycemia exceeding 1000mg/dl , 
high plasma osmolality > 380 mOsm/kg , no significant acidosis orserum 
/ urine ketones . It occurs in type 2 DM especially when age is greater 
than 65 .  Restricted fluid intake due to illness , poor thirst response in 
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elderly, immobility contributes to severe dehydration and 
hyperosmolality. 
 
Figure - 4 Pathophysiology of DKA & HHS 
Table 6 -Clinical features of DKA & HHS 
Diabetic ketoacidosis Hyperosmolar 
hyperglycemic state 
Develops over 1-2 days  Develops gradually over weeks 
Nausea and vomiting Stupor or coma 
Abdominal pain Profound dehydration  
Fatigue and  thirsty Polyuria ( several weeks) 
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Table 7 - Diagnostic criteria 
 
Complications of DKA and HHS 
 Cerebral oedema, pulmonary oedema due to excess fluid, 
hypoglycaemia,  hypokalemia,  cortical vein thrombosis. 
Hypotension and tachycardia Hypotension and tachycardia 
Kussmaul respiration, sweet smelly 
breath 
Chronic co-morbidity like 
dementia, immobility and vomiting   
Confusion  or drowsiness Decreased oral intake by concurrent  
Illness 
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Treatment of DKA and HHS 
 
Figure 5 – Treatment of DKA & HHS 
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Diabetic Retinopathy  
It is the most common micro-vascular complications leading to 
blindness in diabetes. Blindness usually results from diabetic macular 
oedema, tractional retinal detachment or non-resolving vitreous 
haemorrhage. Diabetic retinopathy is effectively treatable at early stages 
when patient is asymptomatic , so annual screening of fundus is 
mandatory for all diabetic patients.[12] 
Modifiable Risk Factors  
• Hyperglycemia 
• Hypertension 
• Dyslipidemia 
• Smoking 
Non modifiable Risk Factors 
• Duration of diabetes 
• Age 
• Genetic predisposition 
• Ethnicity 
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Pathophysiological Events in Diabetic Retinopathy 
 
 
 
Figure 6 – Pathogenesis of Diabetic Retinopathy 
 Microangiopathy with vascular occlusion and leakage are the 
hallmarks of diabetic retinopathy .chronic  hypoxia leads to release of 
vascular endothelial growth factor and formation of new blood vessels 
leading to proliferative retinopathy. 
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 Spots or floaters, blurred vision , fluctuating vision , impaired color 
vision, dark or empty areas, vision loss , frequently changing glasses are 
the clinical manifestation of diabetic retinopathy. 
Table 8 – Diabetic retinopathy Classification 
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Figure 7 – Fundus of Normal & Diabetic retinopathy 
 
 
Figure 8 – Fundus of various stages of Diabetic retinopathy 
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Complications of diabetic retinopathy  
 1.Vitreous haemorrhage  
2.Tractional retinal detachment. 
 3.Rubeosisiridis and 
4.Neovascular glaucoma. 
 Digital colour retinal photography, fundus fluorescinangiography, 
perimetry, ultrasound B scan, and optimal coherence tomography are the 
investigatons available for diabetic retinopathy.  Screening of fundus is 
done by opthalmoscope. 
Treatment  
Laser photocoagulation  
Vitrectomy 
Intravitreal injections of anti-VEGF like Bevacizumab. 
Diabetic nephropathy 
Diabetes is the most common cause of CKD in adults. Proteinuria 
is the hallmark of diabetic nephropathy. Domenico Cotugno was first to 
describe proteinuria in diabetes. Patient gradually develops decline in 
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GFR accompanied by rise in blood pressure and urinary albumin 
excretion. 
 It is defined by persistent albuminuria ( > 300 mg/day ) on at least 
two occasions separated by 3-6 months[13] 
Carl Erik Mogensen classification  
1. Stage of renal hypertrophy and glomerular hyperfiltration . 
2. Stage of apparent normalcy : clinically silent and last for 5 – 15 
years 
3. Stage of incipient nephropathy: microalbuminuria and 
reversible with tratment 
4. Stage of overt nephropathy: macroalbuminuria, nephrotic 
syndrome hypertension and decline in GFR occurs; this stage is 
irreversible. 
5. End stage renal disease: GFR < 15 ml/min , requires renal 
replacement therapy. 
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Figure 9 – Diabetic nephropathy Natural course 
Screening  
 All type 2 DM at the time of diagnosis and then yearly, after 5 
years onset of type 1 DM and then yearly. Screening of diabetic 
nephropathy is done by urine examination .spot albumin to creatinine 
ratio, 24 hr protein collection , timed urine collection are the tests 
available for screening. 
Treatment  
 DCCT (Diabetes Control and Complications Trial) has shown strict 
glycemic control ( HbA1C <7) reduce the risk of developing 
microalbuminuria and also slow the progression of microalbuminuria to 
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overt nephropathy. ACE inhibitors or ARB either one drug can be used to 
prevent microalbuminuria or reduce the severity of macroalbuminuria.[14] 
. Hypertension which is usually present at stage 4 should be 
managed effectively and target is 125/75 mmHg. In absence of 
proteinuria BP goal is 130/80.  Coronary vascular disease is the common 
cause of death in diabetic nephropathy. So dyslipidemia needs to be 
treated with statins. 
Diabetic neuropathy  
 It is characterised by damage to nerve leading to loss of sensation , 
ulceration and subsequent amputation. It occurs as a result of 
microangiopathy, symptomatic and asymptomatic neuropathy develop in 
DM gradually due to hyperglypacemia and hypoinsulinemia. 
Pathogenesis  
1. Metabolic hypothesis  - persistent hyperglycemia, alteration of 
sorbitol pathway , production of glycosylated end products, 
oxidative nerve damage. 
2. Immune hypothesis – autoantibodies to gangliosides , immune 
mediated nerve damage. 
3. Microvascular hypothesis –impaired vasoconstriction and 
vasodilation leading to nerve ischemia. 
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4. Neurotrophic hypothesis – nerve growth factor, neurotrophin 
4/5 are deficient in diabetes. 
5. Oxidative stress hypothesis – increased free radical formation in 
diabetes. 
Pathogenesis 
 
Figure 10 – Pathogenesis of Diabetic neuropathy 
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Classification 
 
 
Figure 11- Classification of Diabetic neuropathy 
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Figure 12 – Diabetic neuropathy Presentation 
Macrovascular complications  
Cardiovascular disease 
 Diabetes have two to four field increase for coronary heart disease 
and heart failure when compared to non diabetes .Coronary heart disease 
is the common cause of death in diabetes[15]. Both systolic and diastolic 
heart failure occur in diabetes. In diabetes , heart failure occur due to 
multiple factors like ischemia , metabolic and functional myocardial 
derangements. 
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Screening  
1. Resting ECG. 
2. Exercise ECG. 
3. Stress myocardial perfusion imaging. 
4. Stress echocardiography. 
5. Cardiac computed tomography 
6. Cardiac MRI 
7. Angiogram 
Screening of cardiovascular disease in diabetes can be done by 
above test. Choice of screening is based on patient symptoms, cost, 
availability. 
Obesity  
 Obesity is result of imbalance between higher energy intake and 
lower energy expenditure in the background of genetic susceptibility. 
Parameters used to measure obesity 
1. Body mass index   
2. Waist circumference  
3. Waist – hip ratio 
4. Body fat percentage 
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Figure 13 – Obesity classification 
Body mass index = weight (kg)/ height 2(m). BMI > 23 is 
overweight and > 25 is obese in indian population. 
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Figure 14 – Medical problems in Obesity 
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ZINC  
 Zinc is an essential trace element. Before discovery of zinc as a 
metal, it is used as zinc salts for medical purposes. Persians used zinc 
vitriol solution to treat eye inflammation. In india metallic zinc was 
produced around 1200 AD. Copper – zinc alloy brass was found in 
literature around 1400 – 1000 BC[16] 
Zinc metabolism 
 Dietary zinc is absorbed in small intestine. Phytates and iron 
inhibits absorption of zinc. Normal value of zinc in blood is in the range 
of 70 – 120 microgram/dl. 60% bound to albumin and 30% bound to 
macroglobulin .zinc is mostly stored intracellularly and bound to 
metalloproteins. Zinc is primarily stored in liver and kidney. 
Functions of zinc 
 1. Zinc is co factor for more than 70 enzyme systems which 
includes dehydrogenases, carbonic anhydrase, carboxypeptidase and 
alkaline phosphatase. 
 2. Regulates nucleoproteins and plays important role in growth, 
tissue repair and wound healing. 
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 3. It plays a role in insulin storage and secretion and involved in 
carbohydrate metabolism. 
 4. Zinc plays a role in immune function .its deficiency is associated 
with  infection. Zinc has inhibitory effect on cholera toxin and E. coli 
heat labile toxin. 
 5. It plays a role in testicular harmone synthesis and gonadal 
function. 
 Recommended dietary allowance for adult is 11mg/day and 
children is 8 mg/day. Dietary sources of zinc include animal products, 
milk, egg, nuts , legumes and cereals. 
Zinc deficiency  
 1.Severe growth retardation. 
 2. Frequent infections especially diarrhoea and pneumonia. 
 3. Hypogonadism. 
 4. Anemia. 
 5. Bullous pustular dermatitis , rough skin. 
 6. Alopecia. 
 7. Impaired taste and smell. 
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Figure 14 – Zinc rich foods 
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Pancreas and zinc 
  Pancreas is both an exocrine and endocrine organ . It secretes 
insulin and glucagon which plays important role in maintaining blood 
glucose in normal range.Pancreas also secretes trypsin , amylase and 
lipase which plays a role in protein , carbohydrate and lipid metabolism 
respectively.so zinc deficiency alter pancreas endocrine metabolism and 
affect glycemic status.  
 
Figure 16 – Zinc transport in Pancreas 
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 (A) Zip1, Zip10, Zip 14 are located in alpha pancreatic cell and 
plays a role in zinc transport into pancreatic cell. Zinc after binds with 
ATP dependent potassium channel and and efflux and inactivates voltage 
dependant calcium channel and decrease glucagon secretion in alpha cell. 
 (B) Zip4 involves in transport of zinc into beta pancreatic cell and 
then ZnT8 helps zinc entering into insulin granules .zinc helps in 
secretion of insulin from beta pancreatic cell.  
 (C) Zip5 helps zinc transports into pancreatic acinar cell and then it 
enters zymogen granules with the help of ZnT2 . Trypsin, amylase and 
lipase are secreted with the help of zinc from zymogen granules. 
Zinc and Diabetes mellitus 
 Zinc dysregulation is associated with both type 1 and type 2 DM. 
Zinc deficiency is associated with decrease insulin release from pancreas 
and hyperglycemia . 
  Zinc deficiency is associated with decreased insulin sensitivity in 
rat offspring. Its deficiency is also associated with weight gain in rat 
offspring. Severe zinc deficiency is associated with hyperglycemia and 
hyperinsulinemia and implicating  zinc role in glucose regulation[17]Apart 
from zinc , zinc transporter (ZnT8) is also implicated in pathogenesis of 
diabetes mellitus. ZnT8 helps zinc enter into insulin granules and then 
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insulin secretion. In animal study ZnT8 knock out mice becomes glucose 
intolerant after eating high fat diet indicating under physiological 
stressful condition (eg obesity) ZnT8 is essential for glucose control. 
 Antibodies formed against ZnT8 is associated with diabetes 
mellitus. these  antibodies are seen in 60 to 70% of newly diagnosed type 
1 DM. this indicates  ZnT8 dysfunction is associated with impaired 
glucose control. 
 Zinc supplementation (Zn(11)-thioallixin-N-methyl) given to 
mouse model of type 2 DM is associated with lowered blood glucose. In 
another study mice were given zinc enriched water for 1 week before 
administering streptozotocin and these mice were from streptozotocin 
induced diabetes. 
 Zinc increases metallothionen level in pancreas and scavenges free 
radicals in pancreas .this protects beta cell from destruction and maintains 
insulin homeostasis. Thus zinc therapy may be beneficial in Diabetes 
mellitus. 
Oxidative stress and Zinc 
 In diabetes, oxidative stress damage to cell is the end result of both 
microvascular and macrovasular complications. Zinc and copper are anti 
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oxidants. Zinc due to its antioxidant property decreases both micro and 
macrovascular complication in diabetes. 
 Metallothionein is cysteine rich compound which has active site for 
zinc. It scavenges free radicals which is responsible for oxidative damage 
to cell. Zinc is an integral part of metallothionein and induces it. 
 Hyperglycemia increases Reactive oxygen species (ROS) 
which causes cell damage .Metallothioneinrelease zinc in response to 
increased ROS .this released zinc antagonise redox active transition 
metals like iron and copper which is responsible for formation of 
hydroxide and superoxide radicals.[18] 
. Zinc also inhibits NADPH oxidase and also it forms integral 
component of Cu/Zn superoxide dismutase which converts superoxide to 
hydrogen peroxide .hydrogen peroxide is then converted to water by 
glutathione zinc. 
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Figure 17 – Antioxidant mechanism of Zinc 
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Zinc and Hypertension 
 Hypertension is defined as blood pressure > 140/90.  Zinc 
deficiency cause taste impairment which leads to high salt 
intake[19]Excess sodium causes water retention and increases blood 
pressure.  
Many enzymes like nitric oxide synthase and angiotensinogen 
converting enzyme that regulate blood pressure contain zinc in their 
structure .nitric oxide produced by endothelial cells plays a role in 
maintaining arterial blood flow and pressure. Zinc is present in nitric 
oxide synthase in the form of zinc thiolate which its active catalytic 
site.[20] 
 Zinc by its antioxidant property decrease oxidative stress to 
vascular endothelium .Zinc deficiency can disrupt endothelial cell 
function and increases oxidative damage .blood pressure rise in zinc 
deficiency depends on age and duration of zinc deficient. 
  Superoxide ion inactivates nitric oxide produced produced from 
endothelium and leads to vasoconstriction and increase in blood pressure. 
Zinc by its antioxidant property decreases superoxide ion and increase 
nitric oxide production and maintains blood pressure. 
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Zinc and Obesity 
 Zinc role in obesity remains unclear. In some studies high leptin 
level in obesity is associated with decreased zinc level in body .in one 
study obese patients with low zinc status have normalised zinc level 
following low caloric diet. 
Zinc and Dyslipidemia 
 Triglyceride and cholesterol levels are high  in zinc deficient 
individual in some studies . exact mechanism is unknown. HDL 
cholesterols increases with zinc supplementation in some studies . 
Zinc and Cardiovascular 
  Zinc supplementation decrease cardiovascular mortality by 
controlling blood glucose, preventing vessel damage by antioxidant 
property and improving HDL cholesterol. 
HbA1c( Glycated haemoglobin)  
 Glycation is a addition of glucose residue to amino group of 
protein. Plasma proteins, haemoglobin , membrane and lens protein 
undergo glycosylation in our body. Among all these proteins 
glycosylation of haemoglobin forms major fraction around 80%. 
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 HbA1c serve as a good indicator of plasma glucose level over past 
3 months. It should be performed at the time of diagnosis and then every 
3 months to assess control of diabetes. 
Table 9 - HbA1c and mean plasma glucose level 
 
1. Nondiabetic range 4.5 – 5.8% 
2. Prediabetic range 5.8 – 6.5% 
3. Diabetic range > 6.5 % 
HbA1c value of less than 4.5 % is associated with serious risk of 
hypoglycaemia. False values occurs in hemoglobinopathies( thalassemia), 
anemia and uremia. Zinc deficiency increases blood glucose and 
increases HbA1c . Fructosamine is another glycated compound which can 
be used to measure mean glucose level for past 2-3 weeks. 
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MATERIALS AND METHODS 
SETTING 
This study was conducted at the Institute of Internal medicine, 
Rajiv Gandhi Government General Hospital and Madras Medical 
College. 
ETHICAL COMMITTEE APPROVAL 
 Obtained. 
STUDY DURATION 
This study was conducted over a period of six months. 
STUDY POPULATION 
Patients attending Medicine outpatient department at Institute of 
Internal medicine 
SAMPLE SIZE 
100 patients , of which 50 are diabetic who attended medicine out 
patient department and 50 are control who attended master health check 
up. 
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DESIGN OF THE STUDY 
 Cross sectional study. 
INCLUSION CRITERIA 
 1.Confirmed cases of  newly diagnosed Type 2 diabetes mellitus in 
the age group 40 to 60. 
 2. Control group with no known comorbidities. 
 3. Patient and control with hypertension and obesity are included in 
this study. 
EXCLUSION CRITERIA 
1. Patient who is taking zinc supplementation or drugs that 
interfere with zinc absorption. 
2. Patient with chronic disease and pregnancy. 
3. Patient with diabetic related complications. 
4. Patient on oral hypoglycemic or insulin. 
ANALYSIS PLAN 
 Statistical analysis was done using SPSS software version 20.0 
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SPONSORSHIP 
 No 
CONFLICT OF INTEREST 
 None  
DATA COLLECTION AND METHODS 
 
Informed consent was obtained from each patient . 
Patients had their history taken according to a Questionnaire and 
were subjected to clinical examination . 
Patients were subjected to investigations like 
HbA1c  
Fasting plasma glucose 
Renal function test 
Fasting lipid profile 
Electrocardiogram 
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HISTORY 
History includes age ,sex address, occupation ,presenting 
complaints, past history, personal history, family history and treatment 
history 
GENERAL EXAMINATION 
 BMI is calculated based on weight and height using the formula 
weight/height in meter square. Blood pressure, pulse and other findings 
are noted.  
SYSTEMIC EXAMINATION 
CARDIOVASCULAR  
RESPIRATORY 
ABDOMEN 
CENTRAL NERVOUS SYSTEM 
FUNDUS OF EYE 
INVESTIGATIONS 
 Serum creatinine -  Alkaline picrate method. 
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Serum urea -   Modified Berthelot method. 
 HbA1c - Automated high performance liquid chromatography. 
Serum Zinc -  End point Nitro PAPS dye binding. 
Serum cholesterol –Cholesterol oxidase method. 
Serum triglyceride –Glycerolkinase peroxidase method. 
Fasting plasma glucose -  glucose oxidase / peroxidase method. 
Urine PCR: urine proteins determined by turbidimetric method 
using 3% sulphosalicylic acid.  
All the investigation were done at lab of Department of 
Biochemistry by well trained technicians. 
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Age distribution in diabetes and control
 
AGE 
41-50 years
51-60 years
Total 
 
 In our study 100 patients are included in which 50 are diabetic and 
50 are contaol. In diabetic 
people are in the age group 51 to 60. In control 29 people  are in the age 
group 41 to 50 and 21 
Figure 18 
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Table 10 – Age distribution 
Diabetes Control
 33 29
 17 21
50 50
33 people are in the age group 41 to 50 and 17 
people are in the age group 51 to 60.
– Age distribution in diabetes and control
-50 51-60
 
 
 
 
 
 
 
 
 
diabetes
control
 Sex distribution in diabetes and control
SEX 
Male 
Female 
  
In our study 25 people are male and 25 
diabetic group. 23 people are male and 27 people are female in control 
group. 
 
Figure 19 
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Table 11 – Sex distribution 
Diabetes 
25 
25 
people are female in 
– Sex distribution in diabetes and control
FEMALE
Control 
23 
27 
 
DIABETES
CONTROL
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Table 11 - Independent sample t test 
 Diabetes Control  
Pvalue Mean SD Mean SD 
HbA1C 8.57 1.51 5.41 0.38 <0.001 
FBS 189.40 51.14 92.04 12.55 <0.001 
Urea 32.90 8.08 30.48 7.90 <0.133 
Creatinine 0.82 0.20 0.78 0.20 <0.341 
BMI 32.48 3.37 29.35 3.36 <0.001 
SBP 132.60 11.97 125.68 11.54 <0.004 
DBP 82.52 7.89 79.88 6.76 <0.076 
ZINC 58.31 17.23 75.65 18.05 <0.001 
Triglyceride 196.58 53.30 173.04 52.27 <0.028 
Cholesterol 225.76 51.90 202.96 50.11 <0.028 
 
  
 HbA1c in diabetes and control
Table 12  
 
Diabetes 
Control 
 
In our study mean HbA1c in diabetic and control group are (8.57 
1.51) and (5.41 + 
value < 0.001). 
Figure 20  
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-Mean and Standard Deviation of HbA1c
Mean SD
8.57 1.51
5.41 0.38
0.38) respectively and it is statistically significant (p 
- Mean HbA1c in diabetes and control
control
HbA1c
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 Fasting Blood Sugar in diabetes and control
Table 13 
 
Diabetes 
Control 
 
 In our study mean fasting blood sugar in diabetic and control are 
(189.40 + 51.14) and (92.04 
significant (p value < 0.001).
Figure 21 
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SD 
51.14 
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 Correlation of Zinc in diabetes and control
Table 14 
 
Diabetes 
Control 
 
 In our study t
which is lower than control group (75.65 
significant ( P value is < 0.001 )
Figure 22 
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Mean 
58.31 
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he mean zinc value in diabetic goup is (58.31
+ 18.05) and statistically 
. 
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SD 
17.23 
18.05 
+ 17.23) 
 
 
 Correlation of BMI in diabetic and control group
Table 15 
 
Diabetes 
Control 
 
 In our studyt
which is higher than control group 
significant ( p value < 0.001 )
Figure 23 
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– Mean and Standard Deviation of BMI
Mean 
32.48 
29.35 
he mean BMI in diabetic group is 
(29.35 + 3.36) 
. 
– Mean BMI of diabetes and control
Diabetes Control
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SD 
3.37 
3.36 
(32.48 + 3.37) 
and statistically 
 
 
 Correlation of B
Table 16 – Mean 
 
Diabetes 
Control 
 
 The mean systolic blood pressure (132.60 
statistically significant (p value < 0.004)in diabetic group whereas mean 
diastolic blood pressure is not statistically significant ( p value < 0.076).
Figure 24 –
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and Standard Deviation of Blood pressure
Mean 
SBP DBP SBP
132.60 82.52 11.97
125.68 79.88 11.54
+ 11.97) is higher and 
 Mean SBP and DBP of diabetes and control
 
Control
 
 
SD 
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 Correlation of dyslipidemia in diabetic and control
Table 17 – M
 
Triglyceride 
Diabetes 
Control 
 
 In our study mean cholesterolin diabetic group 
higher than control 
value<0.028). Mean triglyceridein diabetic group
higher than control
value<0.028). 
Figure 25 – Mean 
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ean and Standard Deviation of Triglyceride & 
Cholesterol 
Mean 
 Cholesterol Triglyceride
196.58 225.76 53.30 
173.04 202.96 52.27 
( 225.76
( 202.96 + 50.11 ) and statistically significant 
( 196.58 
( 173.04 + 52.27)  and statistically significant
Triglyceride and Cholesterol in diabetes 
and control 
Control
 
SD 
 Cholesterol 
51.90 
50.11 
+ 51.90 ) is 
(p 
+ 53.30  )   is 
 (p 
 
 
Triglyceride
Cholesterol
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Table 18 - Correlation of Zinc with various parameters in 
diabetes and control. 
Parameters  
  Correlation coefficient         P value 
Diabetes  Control  Diabetes Control 
HbA1c -0.543 -0.120 <0.001 <0.408 
Fasting blood sugar -0.553 -0.084 <0.001 <0.563 
Body mass index -0.492 -0.161 <0.001 <0.264 
Systolic blood pressure -0.351 -0.103 <0.012 <0.477 
Diastolic blood pressure -0.422 -0.146 <0.02 <0.311 
Triglyceride  -0.451 -0.045 <0.001 <0.756 
Cholesterol -0.422 -0.046 <0.001 <0.749 
 
 
 
 
 
 Correlation of Z
Table 19 
 
 In our study diabetes is divided into three groups based on HbA1c 
Mean zinc value 
significant (p value <
HbA1c in diabetes and control are 
correlation is  higher for diabetes than control
Figure 26 
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inc with HbA1c in diabetes
– HbA1c and Zinc correlation
decreases with increase in HbA1c and statistical
0.001). Pearson correlation coefficient for zinc and 
-0.543 and -0.120 respectively and 
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– HbA1c and Zinc correlation
8 to 10 >10
Zinc & HbA1c 
No of diabetes Mean Zinc value
24 
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. 
ly 
 
 
 
60.27 
55.80 
39.30 
 Correlation of zinc and FBS in diabetes
Table 20 
FBS 
<200 
201-300 
>300 
 
Mean zinc value decreases with increase in FBS and statistically 
significant (p value <0.001). Pearson correlation coefficient for zinc and 
FBS in diabetes and control are 
correlation is higher for diabetes than control
Figure 27 
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– FBS & Zinc correlation 
No of diabetes Mean zinc value
26 
18 
6 
-0.553 and -0.084 respectively and 
. 
– FBS and Zinc correlation 
180-250 >250
Zinc & FBS
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 Correlation of Zinc with BMI in diabetes
Table 21  
BMI 
20 – 30 
30 – 35 
35 – 40 
 In our study diabetes is divided in to three group based on BMI . 
Mean zinc value decreases with increase in BMI and statistically 
significant (p value <0.001).
BMI in diabetes and control are 
correlation is  higher for diabetes than control
Figue 28 
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- Zinc and BMI correlation 
No of diabetes Mean Zinc value
15 
24 
11 
 
Pearson correlation coefficient for zinc and 
-0.492 and -0.161 respectively and 
. 
– BMI and Zinc correlation 
- 30 31 - 35 36 - 40
Zinc & BMI
 
65.48 
59.9 
45.33 
 
 Correlation of Zinc and Triglyceride
Table 22 
Triglyceride 
<150 
151– 250 
>250 
 
Mean zinc value decreases with increase in triglyceride value in 
diabetes and it is statistically significant ( p value 0.001)
correlation coefficient for zinc and triglyceride in diabetes and control are 
-0.451 and -0.045 respectively and correlation is  higher for diabetes than 
control 
Figure 29 
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 Correlation of Zinc and cholesterol
Table 23 
Cholesterol 
< 200 
201 – 250 
>250 
 
 In our study mean zinc value decreases with increase in cholesterol 
in diabetes and it is statistically 
for zinc and cholesterol in diabetes and control are 
respectively and correlation is  higher for diabetes than control
Figure 30 
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Correlation of Zinc and Blood Pressure in diabetes 
Table 24 – Zinc and SBP correlation 
Systolic blood pressure No of diabetes Mean Zinc value 
< 120 8 69.12 
121 – 140 31 58.29 
>140 11 51.8 
 
Table 25 – Zinc and DBP correlation 
Diastolic blood pressure No of diabetes Mean Zinc value 
< 80 24 64.5 
80 – 90 19 53.2 
>90 7 50.7 
 
In our study mean zinc value decreases with increase in blood 
pressure in diabetes. Pearson correlation coefficient for zinc and systolic 
blood pressure in diabetes and control are -0.351 and -0.103 respectively 
and correlation is  higher for diabetes than control.Pearson correlation 
coefficient for zinc and diastolic blood pressure in diabetes and control 
are -0.422 and -0.146 respectively and correlation is  higher for diabetes 
than control 
 Figure 
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Discussion 
 In our study 100 patients (50 diabetic and 50 control) were 
subjected to history, examination and investigations after getting their 
consent.only newly diagnosed type 2 DM without complications 
attending medicine department were included as cases in the study. 
 It wasobserved mean HbA1c, fasting blood sugar, hypertension, 
body mass index, triglyceride, cholesterol, systolic blood pressurein 
diabetes were found to be significantly higher than control. Urea, 
creatinine and diastolic blood pressure were not statistically significant. 
This showed diabetes have increased association with dyslipidemia , 
hypertension and obesity than control. Insulin resistance and other 
unknown mechanism was involved in pathogenesis of this association.  
Zinc and HbA1c 
Mean zinc value of diabetes was 58.31 +17.23  significantly lower 
than control ( 75.65 + 18.05) and it was statistically significant (p value 
<0.001). This correlated with study conducted by McNair et al., in his 
study serum zinc was inversely related to glycemic status of diabetes. 
Garg et al ., also reported similar findings in diabetes. Williams et al., 
observed 17% decrease in Zinc concentration in diabetes while 
comparing with controls.[21] 
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 In our study pearson correlation coefficient of Zinc and HbA1c in 
diabeteswas -0.543 which established strong negative correlation and 
statistically significant ( p value < 0.001) whereas correlation coefficient 
of control for these two parameters was  -0.120 and not significant (p 
value 0.408). 
Tripathy et al., in his study showed negative correlation between 
Zinc and HbA1c with ‘r’ value of  -0.408.[22] 
Zinc & Fasting blood glucose 
 In our study mean fasting blood sugar was significantly higher in 
diabetic than control and pearson correlation coefficient of zinc and FBS 
showed significant  negative correlation in diabetes ( - 0.553)compared to 
control (- 0.084). our study showed serum zinc deficiency occur with 
increase in glycemic status.. 
Zinc and Obesity 
In our study mean BMI was significantly higher in diabetes than 
control. our study showed obesity was associated with type 2 DM. 
Association between diabetes and obesity was shown by many studies . 
Mokdad et al., in his study showed strong association between DM and 
BMI using data from Behavioral Risk Factor Surviellance System.[23]. 
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Our study also showed negative correlation between BMI and zinc in 
diabetes . 
Zinc and dyslipidemia 
 Triglyceride and cholesterol were significantly higher in diabetes 
than control in our study which shows association between dyslipidemia 
and type 2 DM. Insulin resistance in DM was well known reason for 
dyslipidemia. Zinc had negative correlation with triglyceride and 
cholesterol in diabetes in our study .There was only limited study about 
zinc and dylipidemia and more studies were needed to confirm this 
relationship. 
Zinc and hypertension 
 In our study systolic blood pressure was significantly higher in 
diabetes than control whereas diastolic blood pressure was not 
statistically significant. Negative correlation was seen between zinc and 
systolic /diastolic blood pressure in diabetes. 
 Our study showed zinc deficiency occur with increased glycemic 
status. There was also association between zinc and obesity/dyslipidemia/ 
hypertension in diabetes .Large scale studies were needed to prove 
correlation between zinc and obesity/dyslipidemia/hypertension. 
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  Studies had shown zinc deficiency in diabetes increase and fasten 
both micro and macrovascular complications. So detecting zinc 
deficiency in diabetes earlier help in preventing complications and also 
controlling glycemic status. 
In 2006 Al-Maroof et al., study showed zinc supplementation had 
beneficial effects in improving glycemic control in diabetes. His study 
included 133 diabetic cases and they were given zinc supplementation for 
3 months which showed significant decrease in HbA1c[24] 
In 2007 Beletate et al., study showed no evidence of zinc 
supplementation in preventing type 2 DM from insulin resistance.[25]. 
This study included 128 insulin resistance cases and they were given zinc 
supplementation for 3 months. 
Large scale studies are needed to support zinc supplementation in 
type 2 DM to control blood glucose. 
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Conclusion  
1. Zinc deficiency is significantly higher in diabetes than control. 
2. Zinc has strong negative correlation with HbA1c. zinc level 
decreases with increase in HbA1c. 
3. Zinc has strong negative correlation with FBS. zinc level decreases 
with increase in FBS. 
4. Obesity, Systolic hypertension and dyslipidemiaare more frequent 
in diabetes than control. 
5. Zinc also has negative correlation with obesity/ hypertension / 
dyslipidemia in diabetes in our study. 
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ANNEXURES 
  
  
 
“Study of Serum Zinc status and Glycated 
Hemoglobin in Type 2 Diabetes Mellitus”: 
 
 
PROFORMA 
 
 
Name:      Age/Sex: 
Address:      Occupation: 
 
SYMPTOMS: 
 
 
PAST HISTORY: 
 
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
 
FAMILY HISTORY: 
 
TREATMENT HISTORY: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
GENERAL EXAMINATION: 
 
GCS  
 
VITAL SIGNS: 
       PR- 
       BP- 
       RR- 
 
 
       HEIGHT -  
       WEIGHT-  
       BMI- 
 
 
 
SYSTEMIC  EXAMINATION: 
 
CVS: 
 
RS: 
 
ABDOMEN: 
 
CNS: 
 
EYE: 
 
 
  
 
INVESTIGATIONS: 
 
 
SERUM ZINC : 
 
HbA1c : 
 
FASTING BLOOD GLUCOSE : 
 
SERUM UREA : 
 
SERUM CREATININE : 
 
SERUM TRIGLYCERIDE: 
 
SERUM CHOLESTEROL: 
 
ELECTROCARDIOGRAM: 
 
 
 
 
 
 
  
INFORMATION SHEET 
 
We are conducting a study on “Study of Serum Zinc status and 
Glycated Hemoglobin  in Type 2 Diabetes Mellitus” among patients 
attending medicine outpatient department  in Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to 
us. 
           The purpose of this study is to assess serum Zinc level and to 
compare with glycated hemoglobin in Type 2 Diabetes mellitus and 
healthy sujects . 
We are selecting patients based on criteria and if you are found 
eligible, we may be using your blood samples to do tests which includes 
serum Zinc, HbA1c, fasting blood glucose,triglyceride,cholesterol, serum 
urea and creatinine which in any way do not affect your management. 
Thorough history and clinical examination will be done on patients 
who are selected and above mentioned tests will be done on day 1 and 
one fasting blood sample will be taken . 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
 
Signature of Investigator Signature of Participant 
 
 
Date : 
Place : 
 
  
  
 
                                PATIENT CONSENT FORM 
Study Detail : “Study of Serum Zinc status and Glycated Hemoglobin 
in Type 2 Diabetes Mellitus” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered to 
my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research that 
may be conducted in relation to it, even if I withdraw from the study I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from this study. ❏ 
d) I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. ❏ 
 
 
 
Signature/thumb impression 
 
 
Patient’s Name and Address:
Signature of Investigator 
 
 
Study Investigator’s Name: 
Dr. V.Ganesh 
  
 
 
 
 
  
 
 
 
MASTER CHART 
 
MASTER CHART FOR DIABETES  
S.NO AGE SEX HBA1C FBS UREA Creatinine   BMI Triglyceride Cholesterol BP Zinc 
1 40 F 14.8 326 36 1.1 34.3 230 310 130/80 43.9 
2 41 M 10.2 240 26 0.4 33.6 160 174 126/82 42.6 
3 41 M 9.9 223 27 0.8 28.1 145 255 120/80 37.8 
4 58 M 7.3 160 18 0.9 32.4 180 188 136/84 42.4 
5 45 F 11.1 155 30 0.5 36.5 245 284 150/96 32.4 
6 60 F 7.5 170 33 0.9 27 120 210 126/74 77.8 
7 60 F 7.9 120 48 1.2 33.4 186 164 130/80 75.2 
8 45 F 6.7 111 34 0.8 34.2 173 192 142/90 66.5 
9 50 M 10 196 50 1.1 29.8 210 156 128/72 77.8 
10 46 M 9.6 210 42 0.8 33.1 330 246 140/90 50.1 
11 44 F 8.2 136 44 0.5 27.6 126 156 118/70 70 
12 55 F 7.4 140 34 0.9 28.4 137 178 120/80 93.6 
13 42 M 8.6 156 36 0.6 35.3 238 210 150/96 68.1 
14 41 M 10.8 230 38 0.8 32.9 294 255 134/82 43.9 
15 55 M 11.6 290 46 1 36.4 248 226 140/90 36.3 
16 60 M 7 116 14 1.3 29.2 110 184 126/78 82.1 
17 47 F 6.8 124 24 0.9 30.3 148 198 134/80 64.7 
18 56 M 7.3 139 28 0.7 33.1 142 226 144/82 72.5 
19 58 F 8.8 178 36 0.9 33.8 166 245 134/70 92.4 
20 44 F 8.1 167 27 0.9 37.5 258 288 154/98 30.6 
21 55 M 7.9 157 35 0.9 32.4 248 178 126/78 47.8 
22 47 F 7.8 180 36 0.6 32.1 184 253 130/80 55.9 
23 41 F 8.9 199 42 0.7 38 278 326 156/90 33 
24 44 M 8.6 186 44 1.1 30.6 142 237 126/88 47.6 
25 48 M 7.1 166 36 0.8 29.7 112 178 138/82 72.8 
26 43 F 6.9 123 24 0.9 30.4 178 212 126/78 86.7 
27 40 F 10 303 36 1 35.4 164 273 140/90 40.2 
28 40 M 9.3 220 28 0.5 32.7 189 214 118/70 66.7 
29 54 F 8.2 210 30 0.7 27.4 135 124 110/70 64.9 
30 56 M 11.3 320 30 0.9 36.4 178 346 124/86 36.9 
31 60 F 8.4 193 34 1.2 33.5 220 223 128/78 74.5 
32 59 F 7.6 148 36 0.9 29.3 246 176 112/74 76.9 
33 42 M 8.6 164 37 0.6 27.1 214 192 114/68 45.8 
34 45 F 8.8 178 41 0.6 35.3 256 269 136/78 39.5 
35 47 M 9 207 20 0.9 34.8 186 314 134/76 42.3 
36 42 M 6.8 130 40 0.5 36.2 234 295 146/94 85.2 
37 50 M 7.2 156 42 0.8 28.4 128 198 110/72 55.9 
38 52 F 7.7 163 33 1.1 33.2 258 255 126/78 57.3 
39 46 F 7.9 175 31 0.9 31.7 196 214 136/84 64.5 
40 48 M 8.1 168 28 0.7 31.2 188 229 134/86 67.2 
41 44 M 8.8 194 32 0.7 37.9 194 294 152/94 35.9 
42 56 M 8 190 27 0.9 34.2 228 263 140/90 54.2 
43 42 M 7.9 202 34 1.1 27.6 204 146 128/78 49.8 
44 47 F 9.9 267 36 0.9 38.2 312 278 154/94 41.6 
45 43 F 8.7 254 36 0.6 34.5 231 244 140/90 45.9 
46 40 M 8.3 241 40 0.5 39.1 246 285 156/94 51.4 
47 51 M 7.9 220 22 0.7 33.2 173 176 134/86 63.9 
48 53 F 7.4 182 20 0.9 28.9 178 153 132/86 65.4 
49 44 F 7.5 177 18 1 26.3 137 189 118/78 79.2 
50 47 F 8.4 210 26 0.7 31.7 146 209 124/82 66.1 
 
  
MASTER CHART FOR CONTROL 
1 47 F 5.4 104 38 0.5 24.7 110 144 104/68 62.9 
2 49 M 5.2 93 38 0.6 25.6 136 176 110/72 88.4 
3 55 F 4.9 100 37 0.9 27 128 188 114/70 52.4 
4 42 M 5.7 70 28 0.8 27.3 194 214 124/76 80.2 
5 52 F 5.9 93 20 0.8 25.2 220 146 120/80 76.4 
6 49 M 5.5 84 30 0.7 24.8 178 199 120/80 45.2 
7 48 F 5.5 80 24 1 33.1 184 234 132/82 68.4 
8 44 F 5.6 110 44 0.9 33.8 247 267 140/90 93.9 
9 57 F 5.4 111 21 1.1 29.4 124 174 126/82 84.8 
10 54 F 5.2 86 42 1.2 22.6 118 114 118/70 78.5 
11 43 M 5.1 89 26 0.7 28.4 104 163 122/80 74.2 
12 46 F 5.3 74 26 0.7 29.4 206 210 124/84 37.8 
13 45 M 5.3 99 34 0.5 31.1 213 232 138/88 80.2 
14 56 M 4.5 73 30 0.6 30.6 147 192 126/78 76.3 
15 59 F 5.4 81 14 0.9 34.7 188 279 130/80 56.7 
16 42 F 5.5 84 18 1.1 31.8 218 310 136/88 77.9 
17 47 F 5.8 107 29 0.9 27.4 130 175 116/72 112.4 
18 48 F 5.4 96 34 0.6 30.6 136 213 128/72 85.2 
19 51 M 5.4 85 35 0.7 21.4 88 176 100/66 90.2 
20 54 M 5.7 95 39 0.8 30.3 126 145 128/84 47.6 
21 54 F 5.8 94 36 1.1 33.4 164 260 130/80 49.2 
22 48 F 5.5 117 29 0.6 26.3 139 194 120/80 70.1 
23 42 M 5.5 76 40 0.5 25.3 150 166 118/74 120.6 
24 41 F 6.1 119 44 0.5 28.4 155 124 118/76 54.9 
25 54 M 4.8 82 42 0.6 29.7 163 204 126/80 78.3 
26 57 M 5.2 76 34 1.1 30.8 200 194 130/84 85.6 
27 40 M 5.5 81 31 0.9 33.1 224 259 136/86 94.3 
28 52 M 5.1 84 20 0.8 36.2 294 231 150/96 66.2 
29 48 F 6.1 108 26 0.8 26.5 168 193 120/80 114.5 
30 45 F 5.5 96 28 0.6 27.8 163 178 118/76 82.3 
31 44 M 5.8 110 43 0.6 28 157 257 132/78 63.9 
32 49 M 5.5 84 28 0.7 29.3 268 304 120/80 73.8 
33 51 F 4.8 88 31 1.2 30.4 273 326 136/78 82.6 
34 60 F 5.3 88 28 0.9 31.2 203 182 146/92 90.5 
35 44 F 5.7 94 29 0.5 31.8 194 234 120/80 84.5 
36 50 M 5.5 78 30 0.4 28.8 169 134 108/70 77.1 
37 59 F 5.8 99 31 1.2 29.7 184 166 126/74 57.8 
38 40 M 6.3 116 33 0.6 30.2 158 146 128/80 49.8 
39 45 F 5.2 92 40 0.8 37.6 194 267 142/90 66.4 
40 46 M 5.4 83 41 1 32.8 234 198 146/82 72.1 
41 53 F 4.6 96 32 0.7 32.4 312 288 124/78 94.8 
42 57 M 5.5 104 24 0.9 27.6 124 210 124/78 65.3 
43 41 F 4.9 76 25 0.5 27.1 117 180 118/72 116.4 
44 45 M 5.4 108 28 0.9 30.5 168 248 136/90 74.9 
45 55 F 5.1 94 26 0.6 24.3 111 158 100/74 83.1 
46 58 F 5.2 88 16 0.8 27.5 108 166 120/80 62.9 
47 40 M 5.3 81 28 0.9 28.4 94 154 124/84 62.4 
48 42 M 5 96 20 0.8 29.2 145 164 132/86 70.4 
49 54 M 5.1 78 14 0.9 30.2 186 188 126/80 72.9 
50 60 F 6.3 102 40 0.9 34.2 238 224 154/94 75.6 
 
FBS fasting blood sugar 70 - 125mg/dl 
BP blood pressure <140/90 
HBA1C <6.5 
Zinc 70 -150 microgram/dl 
Triglyceride <150mg/dl 
Cholesterol<200mg/dl 
BMI body mass index <23 
 
 
